systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-735Research ArticleСТАТЬИARTICLESИнгаляционный оксид азота у пациентов с идиопатической легочной гипертензией: результаты пилотного исследованияКоносоваИ. Д.noemail@neicon.ruМартынюкТ. В.noemail@neicon.ruЧазоваИ. Е.noemail@neicon.ruИКК им. А.Л.Мясникова ФГБУ РКНПК Минздравсоцразвития РФRussian Federation201209022023915153Copyright © Коносова И.Д., Мартынюк Т.В., Чазова И.Е., 20232023Коносова И.Д., Мартынюк Т.В., Чазова И.Е.Коносова И.Д., Мартынюк Т.В., Чазова И.Е.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/735ReferencesRich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-23.Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-23.Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30.Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30.Moncada S, Palmer R, Higgs E. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43:109-42.Moncada S, Palmer R, Higgs E. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43:109-42.Johnson BD, Beck KC, Zeballos J et al. Advances in pulmonary laboratory testing. Chest 1999; 116: 1377-87.Johnson BD, Beck KC, Zeballos J et al. Advances in pulmonary laboratory testing. Chest 1999; 116: 1377-87.Pepke-Zaba J, Higenbottam TW, Dinh'Xuan AT et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-4.Pepke-Zaba J, Higenbottam TW, Dinh'Xuan AT et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173-4.Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-11.Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-11.Morales-Blanhir J, Santos S, de Jover L et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004; 98: 225-34.Morales-Blanhir J, Santos S, de Jover L et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004; 98: 225-34.Channick RN, Newhart JW, Johnson FW et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996; 109: 1545-9.Channick RN, Newhart JW, Johnson FW et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996; 109: 1545-9.Perez-Penate G, Julia-Serda G, Pulido-Duque JM et al. One-year continuous inhaled nitric oxide for primary pulmonary hypertension. Chest 2001; 119: 970-3.Perez-Penate G, Julia-Serda G, Pulido-Duque JM et al. One-year continuous inhaled nitric oxide for primary pulmonary hypertension. Chest 2001; 119: 970-3.Currie PJ, Seward JB, Chan KL et al. Continuous wave Dopplerdetermination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985; 6: 750-6.Currie PJ, Seward JB, Chan KL et al. Continuous wave Dopplerdetermination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985; 6: 750-6.ATS statement: guidelines for the six-minute walk test. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Am J Respir Crit Care Med 2002; 166 (1): 111-7.ATS statement: guidelines for the six-minute walk test. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Am J Respir Crit Care Med 2002; 166 (1): 111-7.Parsons S, Celermajer D, Savidis E et al. The effect of inhaled nitric oxide on 6-minute walk distance in patients with pulmonary hypertension. Chest 1998; 114 (Suppl. 1): 70S-2S.Parsons S, Celermajer D, Savidis E et al. The effect of inhaled nitric oxide on 6-minute walk distance in patients with pulmonary hypertension. Chest 1998; 114 (Suppl. 1): 70S-2S.Trachsel S, Deby-Dupont G, Maurenbrecher E et al. Association between inflammatory mediators and response to inhaled nitric oxide in a model of endotoxin-induced lung injury. Crit Care 2008; 12 (5): R131.Trachsel S, Deby-Dupont G, Maurenbrecher E et al. Association between inflammatory mediators and response to inhaled nitric oxide in a model of endotoxin-induced lung injury. Crit Care 2008; 12 (5): R131.Christou H, Adatia I, Van Marter LJ et al. Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5'-monophosphate plasma concentrations in newborn infants with persistent pulmonary hypertension. J Pediatr 1997; 130: 603-11.Christou H, Adatia I, Van Marter LJ et al. Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5'-monophosphate plasma concentrations in newborn infants with persistent pulmonary hypertension. J Pediatr 1997; 130: 603-11.
The authors declare that there are no conflicts of interest present.